Physician profile
Parin Parikh
NPI 1376704510
$8,695.18
in general payments reported to CMS, 2019-2025
46 companies · $762 in 2025
The $762 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,776 · 2020: $962 · 2021: $876 · 2022: $1,444 · 2023: $1,509 · 2024: $1,366 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560 · Debt Forgiveness: $55.76 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.29 |
| Debt Forgiveness | $55.76 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $838.74 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $835.58 | 2019-2025 | Lifevest |
| Pfizer INC. | $761.35 | 2019-2025 | |
| Boston Scientific Corporation | $609.99 | 2019-2025 | Mamba, Watchman Access System, Watchman Flx |
| Abiomed | $606.74 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $601.77 | 2019-2025 | |
| Philips North America LLC | $589.80 | 2019-2025 | IV Other |
| Merck Sharp & Dohme LLC | $371.22 | 2021-2025 | Verquvo, Capvaxive |
| Shockwave Medical, INC | $353.30 | 2019-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $254.32 | 2019-2025 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $219.01 | 2019-2024 | Farxiga, Andexxa |
| Esperion Therapeutics, INC. | $194.58 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $172.60 | 2023-2025 | Optimizer, Optimizer |
| Amgen INC. | $172.06 | 2019-2025 | Repatha, Repatha |
| Tela Bio, INC. | $171.43 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parin Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.